Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $7.80 Consensus PT from Brokerages

Key Points

• Gain Therapeutics, Inc. (NASDAQ:GANX) has received a consensus recommendation of "Buy" from five ratings firms, with an average one-year price target of $7.80.
• The company reported a loss of ($0.19) earnings per share, missing the consensus estimate by ($0.02), and is expected to post -1 earnings per share for the current fiscal year.
• Institutional investors have shown increased interest, with Geode Capital Management and Marshall Wace LLP raising their positions significantly during the second quarter.

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have received a consensus recommendation of "Buy" from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $7.80.

A number of research firms have recently weighed in on GANX. Roth Capital cut their price target on Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, August 13th. HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Thursday, July 3rd.

Institutional Trading of Gain Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bridgeway Capital Management LLC acquired a new position in shares of Gain Therapeutics during the 4th quarter valued at about $65,000. Kovitz Investment Group Partners LLC bought a new position in shares of Gain Therapeutics in the first quarter valued at approximately $91,000. Northern Trust Corp lifted its stake in shares of Gain Therapeutics by 88.2% in the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company's stock worth $183,000 after buying an additional 39,642 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Gain Therapeutics during the 4th quarter worth $198,000. Finally, Dauntless Investment Group LLC bought a new stake in shares of Gain Therapeutics during the 1st quarter worth $240,000. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Stock Down 9.4%

Shares of NASDAQ:GANX traded down $0.18 during trading on Friday, reaching $1.74. 2,164,141 shares of the company traded hands, compared to its average volume of 407,815. The firm has a fifty day simple moving average of $1.69 and a 200 day simple moving average of $1.85. The company has a quick ratio of 1.79, a current ratio of 1.79 and a debt-to-equity ratio of 0.09. Gain Therapeutics has a 1-year low of $1.00 and a 1-year high of $3.19. The firm has a market cap of $62.55 million, a P/E ratio of -2.76 and a beta of 0.14.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.